Scalp Cooling and Hair Preservation: What the Research Shows

Scalp cooling is one of the few areas in this whole subject where there is real randomized trial evidence rather than testimonials. That makes it worth looking at carefully, and it also makes it worth being precise about what the numbers do and do not say. Roughly half of participants in the pivotal trial kept enough hair to go without a wig. Roughly half did not.

This is a treatment decision, and it belongs with your oncology care team. They know your regimen, your dose schedule, your cancer type and your other risk factors. Nothing here substitutes for that conversation.

The mechanism, in plain terms

Chemotherapy drugs target rapidly dividing cells, which is why hair follicle cells get caught in the crossfire. Cooling the scalp constricts blood vessels and slows metabolic activity in the follicles, which reduces how much drug reaches them and how vulnerable they are while it is there. Modern systems circulate coolant through a fitted cap before, during and after each infusion, holding the scalp at a controlled temperature rather than relying on frozen gel packs.

Regulatory history

A 2024 review published in PMC on expanding the availability of scalp cooling summarizes the clearance sequence: the FDA approved DigniCap in 2015 as the first scalp cooling device, and the Paxman scalp cooling system followed in 2017. Both were subsequently expanded beyond breast cancer, with the DigniCap system cleared for patients with solid tumors in 2017 and the Paxman system cleared for breast cancer and all other solid tumors in 2018. So availability is much broader now than it was a decade ago, though access still varies by treatment center.

What the randomized evidence shows

The SCALP randomized clinical trial, published in JAMA in 2017, enrolled 182 women with breast cancer requiring chemotherapy across seven US centers. At the interim analysis of 142 evaluable patients, hair preservation succeeded in 48 of 95 women in the cooling group (50.5 percent) compared with 0 of 47 women in the control group (0 percent). The trial was stopped early because the efficacy result crossed the predefined superiority boundary.

Two honest readings of that sit side by side. It is a genuinely large effect against a control arm where literally nobody preserved hair. It is also a coin flip at the individual level, and it varies by regimen. The same review reports success rates across studies ranging from roughly 50 to 84 percent depending on the drug protocol, with taxane-based regimens generally doing better than anthracycline-based ones.

Tolerability and side effects

In the SCALP trial, 54 adverse events were reported in the cooling group, all grades 1 and 2, with no serious adverse device events. In practice the complaints people describe are cold-induced headache, chills, and neck or shoulder discomfort from wearing a cold, snug cap for hours. Sessions also add time to each infusion day, since cooling runs before and after the drug is given.

The scalp metastasis question

The theoretical worry that slowed adoption in the United States was whether cooling the scalp might shelter cancer cells there. A systematic review and meta-analysis of scalp cooling and scalp metastasis risk examined this directly. Among patients who used scalp cooling, scalp metastases occurred in 12 of 1,959 (0.61 percent), compared with 5 of 1,238 (0.41 percent) among those who did not, a difference that was not statistically significant. The authors concluded that scalp cooling does not increase the incidence of scalp metastases.

That is reassuring rather than absolute, as observational data always is. It is a reasonable thing to raise with your oncologist, and they can speak to your specific cancer type.

Planning around a 50 percent result

Because the outcome is uncertain, many people arrange coverage regardless. The National Cancer Institute advises buying a wig while you still have hair so you can match your color, which is good advice whether or not you attempt cooling. Preserving hair often means keeping thinner hair rather than untouched hair, and a topper or a partial piece can bridge that gap.

Cost and availability are real constraints too. Not every infusion center offers it, and out-of-pocket costs are common. Ask your care team what is available and what your plan covers, and confirm coverage with the plan directly.